Employer profile
Ascentage Pharma Group
1 certified H-1B filings across 1 fiscal year.
FY2020 filings
1
FY2020 median
$62k
Top role
Instructional Designer
1 filings
Top state
MD
1 filings
Ascentage Pharma Group has filed 1 certified H-1B Labor Condition Applications over FY2020. In FY2020, its median certified base salary was $62k ($62k–$62k interquartile range). The most-filed role is Instructional Designer (1 filings).
Year-over-year
How Ascentage Pharma Group hired across H-1B fiscal years. YoY column compares to the prior FY.
| FY | Filings | Median $ | YoY % |
|---|---|---|---|
| FY2020 | 1 | $62k | — |
Top job titles
Most-filed positions, across all years (raw DOL titles).
| Job Title | Filings | Median |
|---|---|---|
| Instructional Designer | 1 | $62k |
Top worksite states
Where this employer files.
| State | Filings | Median |
|---|---|---|
| MD | 1 | $62k |
Prevailing wage level distribution
DOL Levels I–IV approximate experience tiers (I = entry, IV = fully competent). A heavy Level I/II skew suggests entry-level / contractor-style hiring; a heavy IV skew suggests senior in-house roles.
Lvl II
1100%
Frequently asked questions
- Does Ascentage Pharma Group sponsor H-1B visas?
- Yes. Ascentage Pharma Group has filed 1 certified H-1B Labor Condition Applications (LCAs) over FY2020. An LCA is a required step before an employer files an H-1B petition; a certified LCA does not by itself guarantee an approved visa.
- What is the median H-1B salary at Ascentage Pharma Group?
- In FY2020, the median certified H-1B base salary at Ascentage Pharma Group was $62k, with a 25th–75th percentile range of $62k–$62k. This is the annual base wage stated on the LCA and excludes bonus, equity, and other compensation.
- What jobs does Ascentage Pharma Group hire H-1B workers for?
- Ascentage Pharma Group's most-filed H-1B role is Instructional Designer (1 filings). Its top worksite state is MD.
- How many H-1B filings did Ascentage Pharma Group submit in FY2020?
- Ascentage Pharma Group had 1 certified H-1B LCA filings in FY2020.